ASCO 2026: key readouts in lung cancer - Pharmaceutical Technology

At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC. At ASCO 2026, companies debuted data that could hold the potential to disrupt the frontline treatment paradigm for various subtypes of NSCLC. Clinical Trials Arena gives you the lung cancer highlights thus far from ASCO 2026. Credit: Keronn art / Shutterstock.com. As professionals from across the oncology landscape gather at the 2026 American Society of Clinical Oncology (ASCO) congress in Chicago, many are looking to key readouts in lung cancer, the leading cause of cancer cases and deaths…

Source: Pharmaceutical Technology